hsp90aa1.1
hsp90aa1.1
Overview
hsp90aa1.1 is a protein-coding target associated with the HSP90 family of molecular chaperones, specifically the Hsp90alpha axis referenced in recent biomedical studies. HSP90 proteins are central regulators of protein folding, stabilization, and client-protein maturation, and they are widely studied in cancer, inflammatory disease, and stress-response biology because many signaling proteins depend on HSP90-mediated chaperoning for functional stability.
In the recent literature provided, hsp90aa1.1 was investigated primarily as a therapeutic target rather than as a standalone diagnostic marker. The studies collectively suggest that HSP90/Hsp90alpha supports the stability of oncogenic and inflammatory client proteins such as PCNA, NLRP3, Akt1, and broader HSP90/PI3K/Akt/mTOR signaling components. This makes the protein relevant to tumor biology, inflammasome regulation, and stress-associated tissue injury, as well as to biomarker development and imaging of HSP90 expression in vivo.
Focus of Latest Publications
Recent publications have focused on hsp90aa1.1 as part of HSP90-targeted strategies across several disease contexts, especially cancer and inflammatory liver disease. In triple-negative breast cancer, bakuchiol was investigated as a natural HSP90-targeting lead using network pharmacology, molecular docking, molecular dynamics, a cell-free N-terminal HSP90 binding assay, and in vitro studies. The compound showed preferential cytotoxicity toward MDA-MB-231 cells, was identified as a competitive N-terminal HSP90 inhibitor, downregulated the HSP90 client protein EGFR, and increased HSP70 expression, consistent with HSP90 inhibition. It also showed anti-proliferative, pro-apoptotic, and anti-metastatic effects, and acted synergistically with doxorubicin.
In oral squamous cell carcinoma, integrative database-driven analyses identified HSP90AA1 and HSP90AB1 among the hub genes associated with poor survival, and linked their expression to PI3K/Akt/mTOR signaling. Hippeastrine was then evaluated through QSAR modeling, docking, molecular dynamics, and in vitro assays in CAL27 and SCC-9 cells. The compound suppressed cell viability, colony formation, migration, and invasion, and western blotting confirmed inhibition of the HSP90-PI3K-Akt-mTOR axis. Rescue with the PI3K activator 740 Y-P reversed the effects on viability and PI3K/Akt phosphorylation, supporting pathway involvement.
Other studies examined hsp90aa1.1 in combination or vulnerability-based settings. In a rat model of metabolic dysfunction-associated steatohepatitis, alvespimycin, an HSP90 inhibitor, combined with fluvastatin improved liver injury, dyslipidemia, oxidative imbalance, inflammasome activation, pyroptosis, and fibrosis more effectively than either agent alone. The combination reduced HSP90, NLRP3, caspase-1, NTGSDMD, and p-SMAD2/3, suggesting that HSP90 inhibition destabilized NLRP3 and contributed to suppression of the ox-LDL-NLRP3-caspase-1-IL-1β/IL-18 axis. In TP53-mutated AML with ribosomal gene loss, chemical screening identified HSP90 inhibition as a selective vulnerability in cases with low ribosomal protein gene expression, linking translational defects to sensitivity to HSP90-targeted intervention.
Additional publications extended HSP90-related work to imaging and target discovery. A novel labeled small-molecule inhibitor-based PET/SPECT tracer targeting HSP90 was developed to improve in vivo detection of tumor HSP90 expression, with enhanced uptake in colorectal and gastric cancer models and reduced liver and kidney retention. In retinal organoid screening, HSP90 inhibitors transiently protected cone photoreceptors but were harmful over longer periods, indicating context- and time-dependent effects. Finally, a screening study for PCNA-targeting compounds unexpectedly identified the Hsp90α inhibitor SNX-2112 as a ligand of PCNA, revealing a new chemical scaffold for PCNA-targeting inhibitor development.